Acrivon Therapeutics, Inc. (NASDAQ: ACRV) witnessed a notable ascent on the US stock exchanges following the close of trading yesterday. Acrivon’s shares surged by 13.47% to reach $10.78 in the after-market session, countering a daytime dip of 3.26% that settled at $9.50. Investor confidence was bolstered after the company held an event to unveil encouraging initial clinical data.
Acrivon (ACRV) convened a corporate Research and Development (R&D) gathering, unveiling preliminary positive clinical findings from the ongoing Phase 2 ACR-368 trials with registrational intent. These trial results provided promising validation for the proprietary ACR-368 OncoSignature biomarker test, exhibiting a confirmed objective response rate (ORR) of 50% in patients grappling with ovarian and endometrial cancers.
Moreover, Acrivon divulged fresh preclinical insights for ACR-2316, now boasting expedited timelines for its Investigational New Drug (IND) application, alongside actionable discoveries utilizing the machine learning-fueled AP3 platform.
In a milestone achievement, Acrivon substantiated the prospective efficacy of its Acrivon Predictive Precision Proteomics (AP3) approach through the ACR-368 OncoSignature assay. This validation demonstrated the capability to pinpoint cancer patients whose tumors are likely to respond favorably to ACR-368 monotherapy.
Acrivon not only underscored its ability to identify and enrich for responders among patients with ovarian cancer but also highlighted the sensitivity of endometrial cancer, a newly identified tumor type predicted to be receptive to ACR-368 by the AP3 platform prior to the initiation of clinical trials.
The R&D symposium afforded Acrivon an opportunity to showcase compelling preclinical data concerning its AP3-based ACR-2316, a dual WEE1/PKMYT1 inhibitor meticulously crafted for enhanced single-agent efficacy. Acrivon revealed expedited timelines for IND filing, now slated for the third quarter, with the possibility of commencing clinical studies in the fourth quarter of the current year.
This demonstration reflects Acrivon’s confidence in the potential of this pioneering asset, purposefully engineered for superior single-agent activity, as evidenced by preclinical studies against benchmark inhibitors. It holds promise for addressing substantial unmet therapeutic needs across a diverse spectrum of tumors, particularly in patients confronted with limited treatment alternatives.
